Treatment of BDNF-related disorders using laquinimod

• US 9,585,878 B2
• Filed: 08/09/2010
• Issued: 03/07/2017
• Est. Priority Date: 08/10/2009
• Status: Active Grant

• Current Assignee: Active Biotech AB
• Original Assignee: Teva Pharmaceutical Industries Limited
• Inventors: Hayardeny, Liat
• Primary Examiner(s): Ivanova, Svetlana M
• Application Number:
  US12/806,275
• Publication Number:
  US 20110034508A1
• Time in Patent Office: 2,402 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/138 Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377
• CPC Class Codes: A61K 31/428 condensed with carbocyclic rings
• CPC Class Codes: A61K 31/4704 2-Quinolinones, e.g. carbostyril
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61K 9/20 Pills, tablets, discs, rods A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095
• CPC Class Codes: A61P 15/10 for impotence
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 27/02 Ophthalmic agents

Abstract

This application provides for a method of increasing brain-derived neurotrophic factor (BDNF) serum level in a human subject comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to increase BDNF serum level in the human subject. The method can further comprise periodically administering to the subject an amount of a second BDNF-increasing agent. This application also provides for a method for treating a human subject suffering from a BDNF-related disease comprising periodically administering laquinimod or a pharmaceutically acceptable salt thereof in an amount effective to treat the human subject. This application additionally provides for use of laquinimod in the manufacture of a medicament for increasing BDNF serum level in a human subject. This application further provides for a pharmaceutical composition comprising an amount of laquinimod effective for use in increasing BDNF serum level in a human subject. This application also provides for a pharmaceutical preparation comprising an amount of laquinimod and an amount of a second BDNF-increasing agent effective for use in increasing BDNF serum level in a human subject.

Claims

1. A method for treating a human subject suffering from Huntington'"'"'s disease, consisting essentially of periodically administering an amount of laquinimod or a pharmaceutically acceptable salt thereof effective to treat the human subject.

2. The method of claim 1, wherein the amount of laquinimod or pharmaceutically acceptable salt thereof is administered to the human subject once daily.

3. The method of claim 1, wherein the periodic administration continues for at least 3 days.

4. The method of claim 1, wherein the amount of laquinimod or pharmaceutically acceptable salt thereof administered is 0.1 mg/day-40.0 mg/day.

5. The method of claim 4, wherein the amount of laquinimod or pharmaceutically acceptable salt thereof administered is 0.6 mg/day.

6. The method of claim 1, wherein the amount of laquinimod or pharmaceutically acceptable salt thereof administered is 0.1 mg/day-0.6 mg/day.

7. The method of claim 1, wherein the amount of laquinimod or pharmaceutically acceptable salt thereof is administered orally.

8. The method of claim 1, wherein the pharmaceutically acceptable salt of laquinimod is laquinimod sodium.

9. The method of claim 6, wherein the amount of laquinimod or pharmaceutically acceptable salt thereof is administered orally.

10. The method of claim 9, wherein the pharmaceutically acceptable salt of laquinimod is laquinimod sodium.